Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
…, CAL Meyer, TM Le, SL Evans-Axelsson… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT) is effective
against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the …
against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the …
[HTML][HTML] Targeted alpha therapy in a systemic mouse model of prostate cancer-a feasibility study
AD Stuparu, CAL Meyer, SL Evans-Axelsson… - Theranostics, 2020 - ncbi.nlm.nih.gov
225 Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients;
however, responses are not durable. We aimed to establish translatable mouse models of …
however, responses are not durable. We aimed to establish translatable mouse models of …
[HTML][HTML] The key role of patient involvement in the development of core outcome sets in prostate cancer
…, R Campi, M Gacci, LUS Evans-Axelsson… - European Urology …, 2021 - Elsevier
Patients are the stewards of their own care and hence their voice is important when
designing and implementing research. Patients should be involved not only as participants in …
designing and implementing research. Patients should be involved not only as participants in …
[HTML][HTML] Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse …
G Canesin, S Evans-Axelsson, R Hellsten… - PLoS …, 2017 - journals.plos.org
Prostate cancer patients with high WNT5A expression in their tumors have been shown to
have more favorable prognosis than those with low WNT5A expression. This suggests that …
have more favorable prognosis than those with low WNT5A expression. This suggests that …
[HTML][HTML] Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
K Witt, S Evans-Axelsson, A Lundqvist… - Cancer Immunology …, 2021 - Springer
There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer.
Combining immunotherapy with other targeted therapies may be an effective strategy for …
Combining immunotherapy with other targeted therapies may be an effective strategy for …
Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of …
…, A Bjartell, G Canesin, S Evans-Axelsson… - Journal of Medicinal …, 2016 - ACS Publications
The transcription factor STAT3 is a potential target for the treatment of castration-resistant
prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of …
prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of …
Radioimmunotherapy for prostate cancer—current status and future possibilities
S Evans-Axelsson, OV Timmermand, A Bjartell… - Seminars in nuclear …, 2016 - Elsevier
Prostate cancer (PCa) is one of the most common cancers in men and is the second leading
cause of cancer-related deaths in the USA. In the United States, it is the second most …
cause of cancer-related deaths in the USA. In the United States, it is the second most …
Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free …
This study investigated the feasibility of targeting the free, unbound forms of prostate-specific
antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced …
antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced …
Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F] AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors
K Lisova, M Sergeev, S Evans-Axelsson… - Nuclear medicine and …, 2018 - Elsevier
Background Peptides labeled with positron-emitting isotopes are emerging as a versatile
class of compounds for the development of highly specific, targeted imaging agents for …
class of compounds for the development of highly specific, targeted imaging agents for …
[HTML][HTML] Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
K Lückerath, L Wei, WP Fendler, S Evans-Axelsson… - EJNMMI research, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT)
is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). …
is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). …